Pharma BD Deal Intelligence
Merck paid up to $2.2B for Peloton Therapeutics to acquire belzutifan (Welireg), a first-in-class HIF-2alpha inhibitor for VHL-associated renal cell carcinoma. The deal added a novel mechanism targeting a transcription factor previously considered undruggable to Merck's oncology portfolio.
Merck will acquire privately held Peloton for $1.05 billion in cash and another $1.15 billion contingent on certain commercialization goals, for a total…
FDA approved Welireg for advanced PPGL (LITESPARK-015), third indication after VHL and RCC.
Merck today announced it has entered into a definitive agreement to acquire Peloton Therapeutics, a clinical-stage biopharmaceutical company focused on the…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Merck acquired privately held Peloton Therapeutics for up to $2.2 billion ($1.05 billion upfront plus $1.15 billion in milestones), gaining PT2977 (belzutifan/Welireg), a novel oral HIF-2α inhibitor in late-stage development for renal cell carcinoma.
82K US cases/yr · $4.6B Global RCC Market (2023) · $350M Welireg Revenue (2024)
Renal cell carcinoma accounts for ~90% of kidney cancers with ~82,000 new US cases/year. Welireg (belzutifan), a novel HIF-2alpha inhibitor acquired via Peloton Therapeutics, is approved for VHL-associated RCC and expanding into broader RCC treatment.
First-line RCC: IO-TKI combos dominate (Keytruda+Lenvima, Opdivo+Cabometyx). Welireg's initial niche is VHL disease (approved 2021) with expansion into advanced RCC. HIF-2alpha inhibition is a novel mechanism validated in the clear cell RCC biology where VHL loss drives HIF-2alpha accumulation.
300 US cases/yr · $200M VHL Treatment Market (2024)
Von Hippel-Lindau (VHL) disease is a rare autosomal dominant hereditary cancer syndrome caused by germline pathogenic variants in the VHL tumor suppressor gene on chromosome 3p25, with an incidence of approximately 1 in 36,000 live births. Loss of VHL function impairs degradation of hypoxia-inducible factors (HIF-1alpha and HIF-2alpha), driving pathologic angiogenesis and tumor formation. Characteristic lesions include CNS and retinal hemangioblastomas, clear cell renal cell carcinoma and renal cysts, pheochromocytomas and paragangliomas, pancreatic neuroendocrine tumors and cysts, endolymphatic sac tumors, and epididymal/broad ligament cystadenomas. Clinical presentation varies by lesion location and includes vision changes, headache, ataxia, hypertension, hematuria, and neurologic deficits; many manifestations are detected through surveillance. Diagnosis is confirmed by germline VHL genetic testing. Lifelong multidisciplinary surveillance (ophthalmologic exam, brain and spine MRI, abdominal imaging, biochemical screening for pheochromocytoma, audiology) is essential to detect lesions early. Management has traditionally relied on surgical resection of symptomatic or growing tumors, with laser/cryotherapy for retinal lesions; systemic HIF-2alpha inhibition is now available for VHL-associated RCC, CNS hemangioblastomas, and pancreatic neuroendocrine tumors not requiring immediate surgery.
Welireg's VHL approval was based on Study 004 showing 49% ORR in VHL-associated RCC. This addressed a significant unmet need where patients faced repeated surgeries. The VHL approval provided Merck an accelerated path to broader RCC development and validated HIF-2alpha biology.
Merck completed up to $2.2B acquisition of Peloton Therapeutics ($1.05B + $1.15B milestones), gaining PT2977 (belzutifan), first-in-class HIF-2alpha inhibitor.
FDA approved Welireg for VHL-associated tumors, first drug for this rare disease and first HIF-2alpha inhibitor to reach market.
FDA approved Welireg for pheochromocytoma/paraganglioma, third indication following VHL and advanced RCC, expanding toward $1B+ peak sales.
Welireg secured three FDA approvals from first-in-class mechanism. Peak sales $1-1.5B projected. Up-to-$2.2B price well justified. One of Merck's best targeted buys.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Peloton Therapeutics Inc. (this deal) | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
| Merck & Co. Inc. / Prometheus Biosciences Inc. | 2023 | $10.8B | 77 |
← Browse all deals · How we score deals
More: 2019 deals · Merck & Co. Inc. deals · Oncology deals